Foundation for Biomedical Research and Innovation at Kobe (FBRI) - SEAKNIT Biotechnology Co., Ltd. Arrived at WestVac Biopharma to Visit and Exchange
On November 29, 2021, Foundation for Biomedical Research and Innovation at Kobe (FBRI) - Chairman LIU Miaomiao of SEAKNIT Biotechnology Co., Ltd. (hereinafter referred to as "SEAKNIT") and others, arrived at WestVac Biopharma to visit and exchange, and held a symposium with the management team of WestVac Biopharma.

In the course of the symposium, Academician WEI Yuquan on behalf of WestVac Biopharma expressed a warm welcome to SEAKNIT and its entourage. The two sides conducted in-depth exchanges and discussions on topics such as the R&D of recombinant COVID-19 vaccine (Sf9 cells) and clinical trials in Japan. Academician WEI proposed that WestVac Biopharma is actively advancing the clinical trials of the COVID-19 vaccine in Japan and is currently applying for the Emergency Use Authorization (EUA) of the Pharmaceuticals and Medical Devices Agency (PMDA) of the Japan Independent Administrative Corporation, hoping to obtain more support from the Japanese government and SEAKNIT to promote the smooth progress of the project. Meanwhile, it is hoped that both parties can strengthen cooperation for the R&D and clinical trials of the second generation COVID-19 vaccine.

LIU Miaomiao, Chairman of SEAKNIT, said that the enrollment work in the phase II clinical trial of the COVID-19 vaccine carried out by WestVac Biopharma in Japan has been completed. SEAKNIT is willing to work together with WestVac Biopharma to promote the implementation of relevant projects as soon as possible, and actively explore the further schedule of in-depth cooperation.

After the symposium, SEAKNIT and its entourage, accompanied by WestVac Biopharma executives, visited and inspected WestVac Biopharma production base in Chengdu.